2009PubMedRequires access

[Therapeutic cloning and somatic cell reprogramming: every road leads to Rome].

Jin Yang, Guoqiang Liu, Tianpei Hong

Open publisher page 1 citations

Abstract

The researches of therapeutic cloning and somatic cell reprogramming, two strategies used to generate patient-specific autologous stem cells, have recently made great progress. Therapeutic cloning refers to derivation of embryonic stem cells from blastocyst produced by somatic cell nuclear transfer, whereas somatic cell reprogramming refers to establishment of induced pluripotent stem (iPS) cells from differentiated somatic cells by ectopic expression of specific transcription factors. The two strategies differ in their methodological approaches, technical obstacles and ethical debates, but confront similar problems including the differentiation of stem cells and the feasibility of cell-replacement therapy. This review discusses the research advance of these two biotechnologies and summarizes their difference and similarity.

About this research paper

What this paper is about

The researches of therapeutic cloning and somatic cell reprogramming, two strategies used to generate patient-specific autologous stem cells, have recently made great progress. Therapeutic cloning refers to derivation of embryonic stem cells from blastocyst produced by somatic cell nuclear transfer, whereas somatic cell reprogramming refers to establishment of induced pluripotent stem (iPS) cells from differentiated somatic cells by ectopic expression of specific transcription factors. The two strategies differ in their methodological approaches, technical obstacles and ethical debates, but confront similar problems including the differentiation of stem cells and the feasibility of cell-replacement therapy. This review discusses the research advance of these two biotechnologies and summarizes their difference and similarity.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The researches of therapeutic cloning and somatic cell reprogramming, two strategies used to generate patient-specific autologous stem cells, have recently made great progress. Therapeutic cloning refers to derivation of embryonic stem cells from blastocyst produced by somatic cell nuclear transfer, whereas somatic cell reprogramming refers to establishment of induced pluripotent stem (iPS) cells from differentiated somatic cells by ectopic expression of specific transcription factors. The two strategies differ in their methodological approaches, technical obstacles and ethical debates, but confront similar problems including the differentiation of stem cells and the feasibility of cell-replacement therapy. This review discusses the research advance of these two biotechnologies and summarizes their difference and similarity.

Key concepts: Reprogramming, Somatic cell, Induced pluripotent stem cell, Somatic cell nuclear transfer, Embryonic stem cell, Stem cell, Biology, Cell potency

Related papers

Back to paper searchBrowse research topicsOriginal source
[Therapeutic cloning and somatic cell reprogramming: every road leads to Rome]. — Research Paper | ScholarLens